SECuRE trial update
Filed with ASX · · 6 pages · English
On 6ix: 6ix.com/news/secure-trial-update
• Another participant with metastatic castration-resistant prostate cancer (mCRPC) in the Cohort Expansion Phase (Phase II; 8 GBq of 67Cu-SAR-bisPSMA per cycle) of the SECuRE trial (NCT04868604)1 achieved undetectable disease as assessed by prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET). • Undetectable disease by PSA was achieved af
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
- Co-PSMA abstract released
- Quarterly Activities/Appendix 4C Cash Flow Report
- SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
- SECuRE trial to continue with no modifications to protocol
Later from Clarity Pharmaceuticals
- SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET
- Half Yearly Report and Accounts
- AMPLIFY trial - Target number of participants achieved
- Registrational Phase III AMPLIFY trial: Target number of participants achieved
- Co-PSMA data presented
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals